Gilead Sciences Gets a Shot at Next-Gen Cell Therapy With $325M Arcellx Alliance
Gilead Sciences entered cell therapy with a multi-billion dollar acquisition that positioned it to compete with a Novartis treatment for...
Health
Can Hospitals Succeed in VBC and Improve Their Overall Financial Health? An Oxymoron, It Is Not
Value-based care has been viewed primarily as a cost-center to the hospital budget that requires upfront investment in the infrastructure...
As Balwani and Holmes Head To Jail…Will Others in Health Tech Follow? – The Health Care Blog
by MIKE MAGEE This week’s headlines seemingly closed a chapter on the story of medical research criminality in America. Ramesh...
Virtual Reality: The New Tool in Healthcare Training
I don’t think anyone can really be prepared for their first time using a virtual reality headset. Technology has become...
Are We Missing a Vital Sign? Our Diet Can Unfold Answers To Many of Our Health Concerns
African woman opening parcel with meal kit. Imagine a world in which we knew—as in fact we do—that blood pressure...
Healthcare Hires of Note – MedCity News
1upHealtha FHIR data platform and health data cloud, announced that Pieter De Leenheer has joined the executive team as the...
How Employers Can Support the Food as Medicine Movement
The Food as Medicine movement has been picking up steam recently, as healthcare organizations like Highmark Health, Kaiser Permanente and...
New National Tracker for Non-fatal Overdoses Is ‘a Step in the Right Direction’ to End the Opioid Crisis
The White House launched a new initiative on Thursday to address the country’s opioid crisis — a dashboard tracking non-fatal...
Healthcare Deal Value Expected to Keep Decreasing in 2023, PwC says
Transaction volumes have been rising across the healthcare sector in 2022, driven in large part by private equity, according to...
Mark Cuban’s Cost Plus Drugs Turns Focus to Employers
After launching as a director-to-consumer startup in January, the Mark Cuban Cost Plus Drug Company is turning to the employer...
